1. Home
  2. IART vs ANAB Comparison

IART vs ANAB Comparison

Compare IART & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Integra LifeSciences Holdings Corporation

IART

Integra LifeSciences Holdings Corporation

HOLD

Current Price

$13.23

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

ANAB

AnaptysBio Inc.

HOLD

Current Price

$44.35

Market Cap

1.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IART
ANAB
Founded
1989
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.2B
1.2B
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
IART
ANAB
Price
$13.23
$44.35
Analyst Decision
Hold
Buy
Analyst Count
7
12
Target Price
$15.00
$63.80
AVG Volume (30 Days)
874.9K
751.8K
Earning Date
10-30-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,642,966,000.00
$169,467,000.00
Revenue This Year
$3.26
$135.45
Revenue Next Year
$2.71
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.99
196.42
52 Week Low
$10.87
$12.21
52 Week High
$27.13
$45.32

Technical Indicators

Market Signals
Indicator
IART
ANAB
Relative Strength Index (RSI) 53.66 71.68
Support Level $12.81 $40.52
Resistance Level $13.43 $45.32
Average True Range (ATR) 0.57 2.66
MACD 0.24 0.36
Stochastic Oscillator 78.69 92.89

Price Performance

Historical Comparison
IART
ANAB

About IART Integra LifeSciences Holdings Corporation

Integra Lifesciences Holdings Corp is a New Jersey-based medical equipment company focused on developing products for regenerative therapy, extremity orthopedics, and neurosurgical applications. The firm is organized into two primary segments: Codman specialty surgical and tissue technologies. Codman Specialty Surgical generates maximum revenue from its segmental operations. Integra serves Europe, Asia Pacific, and the rest of the world whilst it derives key revenue from domestic sales.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: